Any of the muscles in the periorbital and facial regions may be targeted with botulinum toxin injection (see Fig. 1 for an anatomic depiction of these muscles). As the toxin acts on the neuromuscular ...
August 3, 2010 — The US Food and Drug Administration (FDA) has approved incobotulinumtoxinA intramuscular injection (Xeomin; Merz Pharmaceuticals) for the treatment of botulinum toxin–naive and ...
Benign essential blepharospasm (BEB), a form of focal dystonia, is a disorder of involuntary spasms involving the eyelid protractor muscles. First reported in Western medical literature in 1857, BEB ...
GREENSBORO, N.C., Aug. 2 - Merz Pharmaceuticals today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Xeomin® (incobotulinumtoxinA), a botulinum toxin type A ...
Blepharospasm: Injection of XEOMIN into the orbicularis oculi muscle may lead to reduced blinking and corneal exposure with possible ulceration or perforation. Lower lid injections should not be ...
Merz Pharmaceuticals today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Xeomin® (incobotulinumtoxinA), a botulinum toxin type A for the treatment of adults ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback